Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Palisade Bio, Inc. on July 8, 2024. The filing details the voting outcomes for director elections and the ratification of the independent registered public accounting firm.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events and does not contain financial performance data.
Material Changes and Voting Results
As of the record date (May 16, 2024), 936,402 shares were outstanding. A total of 380,286 shares (approximately 40.61%) were present, constituting a quorum.
Proposal 1: Election of Directors
Stockholders elected three directors to serve until the 2025 annual meeting. Results were as follows:
| Name | Votes For | Votes Withheld | Broker Non-Votes |
|---|---|---|---|
| J.D. Finley | 141,074 | 11,984 | 227,228 |
| Donald Williams | 139,029 | 14,029 | 227,228 |
| Margery Fischbein | 142,588 | 10,470 | 227,228 |
Proposal 2: Ratification of Accounting Firm
Stockholders ratified the selection of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
| Votes For | Votes Against | Votes Withheld / Abstentions | Broker Non-Votes |
|---|---|---|---|
| 370,358 | 7,697 | 2,231 | 0 |
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Meeting Date: July 8, 2024.
- Quorum Status: Achieved with 40.61% of outstanding shares present.
- Board Composition: J.D. Finley, Donald Williams, and Margery Fischbein were re-elected.
- Auditor: Baker Tilly US, LLP was ratified for the 2024 fiscal year.
- Share Count: 936,402 shares outstanding as of the May 16, 2024 record date.